145
Participants
Start Date
May 7, 2019
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2026
glepaglutide
Glucagon-Like Peptide-2 (GLP-2) analog
Mount Sinai Hospital, New York
Georgetown University Medical Center, Washington D.C.
Cleveland Clinic, Cleveland
Universitätsklinikum Bonn, Bonn
Mayo Clinic College of Medicine, Rochester
University of Chicago Children's Hospital, Chicago
University of Nebraska Medical Center, Omaha
Vanderbilt University Medical Center, Nashville, Nashville
UZ Leuven, Leuven
The Royal Alexandra Hospital, Edmonton
University Health Network - Toronto General Hospital, Toronto
Rigshospitalet, Copenhagen
Hôpital Beaujon, Clichy
Centre Hospitalier Lyon-Sud, Pierre-Bénite
Charité - Universitätsmedizin Berlin, Berlin
Universitätsklinikum Frankfurt - Med. Klinik I, Frankfurt
Asklepios Kliniken Hamburg GmbH, Hamburg
Universitätsmedizin Rostock, Rostock
UMC Radboud Nijmegen, Nijmegen
Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi, Lodz
Solumed, Poznan
Szpital Skawina sp. z o.o. im. Stanley Dudricka, Skawina
St Mark's Hospital, Harrow
UCLH Foundation NHS Trust, London
University of East Anglia, Norwich
University Hospital Southampton NHS Foundation Trust, Southampton
Western University, London
Lead Sponsor
Zealand Pharma
INDUSTRY